26 C
Byron Shire
March 23, 2023

TGA grants Provisional approval of oral COVID-19 treatments

Latest News

Nationals and Labor didn’t sign Clarence anti-mining pledge

The Clarence Catchment Alliance (CCA) have been seeking the support of all candidates running for the seat of Clarence...

Other News

Free Julian Assange rally in Lismore

Supporters of Julian Assange gathered outside Lismore Baths on Saturday, the 20th Anniversary of the Iraq war, to add their voice to those who would see the journalist free.

Seat of Lismore has 1,000 new constituents after Electoral Commission redistribution

There are about 1,000 new constituents in the Byron Shire hinterland who at this Saturday’s election come into the Electorate of Lismore because of a NSW Electoral Commission redistribution.

Dredging rivers: what are the Ballina candidates’ positions?

A recent Meet the Candidates evening in Ocean Shores saw discussion around how to manage local river systems, which have silted up over generations, and likely contributed to the high flood levels experienced in 2022.

Nicola Levi supports a ban on mining in the Clarence

Independent Nicola Levi supports banning mining in The Clarance catchment and does not support a thermal waste incinerator at...

Have you got a funny kid?

Do you have a funny kid? The search for Australia’s funniest teens is making its way across the nation and three is a free workshop coming to Brunswick Heads

Lismore candidate Ross Honniball

With just a few days until we head to the polls, The Echo asked the candidates for the seat of Lismore one last bunch of questions.

Merck Sharp & Dohme’s Lagevrio (molnupiravir).

Brought to you by The Echo and Cosmos Magazine

Both medications will be targeted towards people most at risk of severe disease.

At last, some good news on the COVID front: the Therapeutic Goods Administration (TGA) has provisionally approved the first oral antiviral treatments for COVID-19.

Federal Health Minister Greg Hunt has confirmed the government has acquired 500,000 courses of Pfizer’s Paxlovid, and 300,000 courses of Merck Sharp & Dohme’s Lagevrio (molnupiravir), with the first deliveries of both medicines anticipated to arrive in the country in coming weeks.

While attention has lately focused on booster schedules and the necessity of addressing global vaccine equity, these novel effective treatments are crucial additional tools in our arsenal.

The medications hold the promise of significantly reducing the risk of progression to severe disease, potentially enabling many more cases to be treated as outpatients and easing the pressure on our beleaguered hospitals and medical staff.

‘This is such a fantastic advancement and opportunity for effective treatments, designed and tested to specifically target SARS-CoV-2, that can be easily accessed as oral, take-home formulations,’ says Associate Professor Jill Carr, laboratory head in microbiology and infectious diseases in the College of Medicine and Public Health at Flinders University.

Both medications work by inhibiting the replication ability of the SARS-CoV-2 virus.

‘Molnupiravir targets the machinery that replicates the viral genome, while Paxlovid targets the viral protease that is essential for infectivity and is formulated with ritonavir, which “boosts” the therapeutic levels of the active drug,’ explains Carr.

Associate Professor Andrew Rowland, Beat Cancer Project mid-career research fellow in clinical pharmacology at Flinders University, adds that Paxlovid targets a unique process in COVID replication that is unrelated to spike proteins, which are the target of most other COVID treatments and vaccines.

‘This means that Paxlovid is less likely to lose efficacy due to mutations in the spike protein, which to date have been associated with the major variants, including Delta and Omicron,’ he says.

Both are designed to be taken every 12 hours over five days from the onset of symptoms, before viral loads reach levels associated with severe disease.

Hunt has flagged that these treatments won’t be available for everyone who contracts COVID-19, being reserved instead for vulnerable patients most at risk of severe disease, including the elderly and those in aged care.

While the arrival of these new treatments offers a significant opportunity to reduce the impact of COVID-19, the medical regulator has stressed that they do not represent a substitute for vaccines.

In a recent interview with Cosmos, Monash University Malaysia molecular virologist Dr Vinod Balasubramaniam reiterated this point.

‘Vaccines offer long-term, robust and durable protection via immunological memory against COVID-19 before the real infection itself, training our body to be ever ready to fight this disease – something an antiviral pill could not provide,’ he said.

‘Vaccination should remain the long-term priority for governments worldwide in the fight against this pandemic. But antiviral strategies should be added as part of our portfolio to fight COVID-19 and future pandemics to give a synergistic effect that will have a better outcome.’

There is additional good news from the TGA on vaccines: Australia will soon offer four different vaccines, with the regulator also provisionally approving the Novavax jab.

Hunt is hopeful this latest vaccine – the only protein-based jab available – will help to encourage the reluctant five per cent of Australians aged 16 and over who remain unvaccinated to step up for their first shot.

Novavax has only applied for its vaccine to be used for primary vaccination courses, meaning it will need to apply for further TGA approval before being use for booster shots.

This article was originally published on Cosmos Magazine and was written by Jamie Priest. Jamie Priest is a science journalist at Cosmos. She has a Bachelor of Science in Marine Biology from the University of Adelaide.

Published by The Echo in conjunction with Cosmos Magazine.

Support The Echo

Keeping the community together and the community voice loud and clear is what The Echo is about. More than ever we need your help to keep this voice alive and thriving in the community.

Like all businesses we are struggling to keep food on the table of all our local and hard working journalists, artists, sales, delivery and drudges who keep the news coming out to you both in the newspaper and online. If you can spare a few dollars a week – or maybe more – we would appreciate all the support you are able to give to keep the voice of independent, local journalism alive.


  1. Last I checked, Pfizer was working to modify Ivermecin just enough to get a patent on it again. If that’s what Paxlovid is, then it should work on all strains of all RNA viruses if given early enough. It will just cost a thousand time more.


Please enter your comment!
Please enter your name here

Not a ‘bonanza for developers and land bankers’ as local councils lose planning controls?

The NSW Department of Planning and Environment were quick to respond to the article ‘A bonanza for developers and land bankers?’ published on 21 March 2023 on The Echo online ‘to correct the inaccuracies contained in your article’.

Janelle’s four year road to the 2023 vote

Yesterday was the fourth anniversary of Janelle Saffin's win in the seat of Lismore and with not a minute to celebrate, Saffin spoke to The Echo about the 2023 campaign.

Appeal to locate woman missing from Tweed Heads

Police are appealing for public assistance to locate a woman, Kara Symington, missing from Tweed Heads since Tuesday.

Election 2023: Crystal ball gazing and hot tips

In a tight election, with many predicting a hung parliament, all eyes are on Sydney seats to see if any Teals can wrest seats from Liberals – and can Labor regain an inner Sydney seat from the Greens?